Browsing "1. Journal Papers" by Author : 4740

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 74 to 96 of 96

This table browses all dspace content
Issue DateTitleJournal Title
2023Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing CANCER RESEARCH AND TREATMENT
2019Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer YONSEI MEDICAL JOURNAL
2021Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2020Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case ReportOCULAR IMMUNOLOGY AND INFLAMMATION
2020Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer CLINICAL CANCER RESEARCH
2022Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck RADIATION ONCOLOGY
2022SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2024SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer JOURNAL OF CLINICAL ONCOLOGY
2011Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.ONCOLOGY
2019Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer EMBO MOLECULAR MEDICINE
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2020The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma JOURNAL OF THORACIC DISEASE
2022The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2023The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer KOREAN JOURNAL OF INTERNAL MEDICINE
2022The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report ESMO OPEN
2022Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 TRANSLATIONAL LUNG CANCER RESEARCH
2022Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer RADIATION ONCOLOGY
2009Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea CANCER RESEARCH AND TREATMENT
2021Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort StudyCLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
2023Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea DRUGS-REAL WORLD OUTCOMES
2023Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer LUNG CANCER
2019YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH
2022YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment FRONTIERS IN CHEMISTRY
12

Browse

Links